Rocket Pharmaceuticals Stock Today
| RCKT Stock | USD 14.20 0.09 0.64% |
Performance0 of 100
| Odds Of DistressLess than 21
|
Rocket Pharmaceuticals is selling for under 14.20 as of the 29th of November 2024; that is 0.64 percent increase since the beginning of the trading day. The stock's last reported lowest price was 13.99. Rocket Pharmaceuticals has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Rocket Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of February 2015 | Category Healthcare | Classification Health Care |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey. The company has 91.16 M outstanding shares of which 11.09 M shares are at this time shorted by private and institutional investors with about 15.0 trading days to cover. More on Rocket Pharmaceuticals
Moving against Rocket Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Rocket Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President COO | PharmD MBA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsRocket Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Rocket Pharmaceuticals' financial leverage. It provides some insight into what part of Rocket Pharmaceuticals' total assets is financed by creditors.
| |||||
Rocket Pharmaceuticals (RCKT) is traded on NASDAQ Exchange in USA. It is located in 9 Cedarbrook Drive, Cranbury, NJ, United States, 08512 and employs 268 people. Rocket Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.29 B. Rocket Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 91.16 M outstanding shares of which 11.09 M shares are at this time shorted by private and institutional investors with about 15.0 trading days to cover.
Rocket Pharmaceuticals currently holds about 321.37 M in cash with (194.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.87.
Check Rocket Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Rocket Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rocket Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rocket Pharmaceuticals. Please pay attention to any change in the institutional holdings of Rocket Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Rocket Ownership Details
Rocket Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 1.6 M | |
| Boxer Capital Llc | 2024-09-30 | 1.5 M | |
| Bank Of America Corp | 2024-06-30 | 1.2 M | |
| Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | |
| Cowen And Company, Llc | 2024-06-30 | 1.1 M | |
| Novo A/s | 2024-09-30 | 1.1 M | |
| Mpm Oncology Impact Management Lp | 2024-09-30 | 1.1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 952 K | |
| Perceptive Advisors Llc | 2024-09-30 | 931.9 K | |
| Rtw Investments, Llc | 2024-06-30 | 17.7 M | |
| Wellington Management Company Llp | 2024-06-30 | 9.2 M |
Rocket Pharmaceuticals Historical Income Statement
Rocket Stock Against Markets
Rocket Pharmaceuticals Corporate Management
| CPA CPA | VP, Officer | Profile | |
| Mayo Pujols | Chief Officer | Profile | |
| Martin JD | Chief Counsel | Profile | |
| Carlos Martin | Chief Officer | Profile | |
| Jonathan Schwartz | Chief Medical Officer | Profile | |
| Aaron Ondrey | Chief Officer | Profile | |
| Isabel JD | Senior Officer | Profile |
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.